Kimberly-Clark (KMB) Q4 2025 earnings review
Portfolio Overhaul Masks Volume Strength; 2026 is a Transition Year
Kimberly-Clark's Q4 2025 results reflect a company in violent transition. While reported sales fell 0.6% due to divestitures (PPE, Private Label Diapers), the core engine is revving: Organic sales rose 2.1%, driven entirely by volume-plus-mix (+3.0%) rather than price (-1.1%). The massive strategic pivot—exiting low-margin Tissue (Suzano JV) to acquire Kenvue (Consumer Health)—dominates the narrative. However, the 2026 guidance brings a reality check: Adjusted EPS is expected to be flat as the company loses income from discontinued operations before realizing Kenvue synergies.
🐂 Bull Case
The era of inflation-led growth is over, and KMB is winning on volume. Q4 volume-plus-mix grew 3.0%, accelerating from 2.7% in Q3. This indicates genuine demand for the 'Powering Care' innovation pipeline rather than just pricing power.
International Personal Care (IPC) is the star performer. While sales grew 4.2%, Operating Profit surged 20.6% in Q4 due to volume leverage and productivity. This segment is effectively carrying the profit growth for the enterprise.
🐻 Bear Case
The core North America business is treading water. Organic growth was an anemic +0.8%, with pricing acting as a drag. The company is having to 'invest in price:value tiers' (read: cut prices/promo) to hold share.
Guidance for 2026 Adjusted EPS is 'flat.' The loss of income from the IFP business (Suzano JV) creates an earnings hole that organic growth and the Kenvue integration haven't yet filled. Investors face a 'gap year' in earnings growth.
⚖️ Verdict: ⚪
Neutral. The strategic logic of swapping low-margin tissue for high-margin consumer health (Kenvue) is sound, and the return to volume growth is excellent. However, 2026 looks like a messy execution year with flat earnings and massive integration risks. The weak North American organic growth (+0.8%) is a specific concern that warrants caution.
Key Themes
The Kenvue Transformation
Management explicitly framed the pending Kenvue acquisition as the 'next powerful step.' This fundamentally alters the investment thesis from a paper/staples company to a Consumer Health giant. This moves the portfolio toward higher-margin, less commoditized categories, justifying the exit from private label diapers and the Suzano JV for tissue.
Productivity Overcoming Deflationary Pricing
KMB is successfully executing a classic margin pivot. While Net Price was a 1.1% headwind in Q4 (investing in value tiers), Adjusted Operating Profit rose 13.1%. How? 'Strong productivity gains' and lower MG&A expenses. The company is self-funding its price competitiveness through efficiency.
North America Pricing Power Eroding
Decelerating. In North America, organic sales grew only 0.8% despite volume growing 2.5%. This implies a negative pricing/mix impact of roughly -1.7%. The competitive environment in US Diapers and Tissue is forcing KMB to spend heavily on 'price investments' to maintain volume, capping top-line expansion.
Discontinued Operations Earnings Hole
The projected flat Adjusted EPS for 2026 is driven by the 'reduction in Income from Discontinued Operations' (the IFP business moving to the Suzano JV). While this improves long-term margin structure, it removes a significant chunk of immediate cash flow and earnings that the remaining business must sprint to replace.
Transformation Costs Weighing on GAAP Results
The gap between Reported and Adjusted numbers remains wide. Q4 Gross Margin was 35.9% reported vs 37.0% adjusted (110bps drag from transformation charges). Full-year operating profit was impacted by $380M in transformation costs. Investors must trust 'Adjusted' metrics heavily, as GAAP numbers are messy.
Other KPIs
Stable. Continued the positive trend (Q3 was +2.5%). Crucially, this is entirely volume-driven (+3.0% Vol/Mix), offset by price investment (-1.1%).
Stable. Flat YoY. Productivity savings were fully offset by 'unfavorable pricing net of cost inflation.' This indicates KMB is passing all efficiency savings back to the consumer to protect share.
Decelerating. Down 3.0% reported, and only +0.8% organic. The exit of the private label diaper business (3.7% headwind) continues to obscure results, but the underlying organic growth is weak.
Decelerating. Down from $3.2B in FY24. The drop is driven by transformation cash costs and working capital timing, despite the 'strong productivity' narrative.
Guidance
Stable. Management expects to grow in line with or slightly ahead of their weighted category growth of ~2%. This implies no significant acceleration from the current 2.1% pace.
Decelerating. Q4 saw +13% growth; the 2026 outlook implies a step down in momentum, likely due to the continued need for price investments and the loss of IFP contributions mid-year.
Decelerating. A sharp drop from the +24% growth seen in 25Q4. The cause is structural: the sale of the IFP business creates an earnings void before the Kenvue acquisition creates accretion.
Reversing. After years of currency headwinds, KMB expects FX to be a significant tailwind in 2026, boosting reported results.
Key Questions
North America Pricing Strategy
With North America organic growth at only 0.8% and pricing net of cost inflation dragging margins, are we entering a deflationary spiral in US Personal Care? How long will 'price investments' be required to hold share?
Kenvue Integration Timeline
With 2026 EPS guided flat due to the IFP exit, when do you anticipate the Kenvue transaction becoming accretive to EPS? Is 2026 a 'kitchen sink' year?
Cash Flow Degradation
Operating Cash Flow fell $400M YoY in 2025 despite strong productivity claims. What are the specific working capital headwinds, and should we expect conversion to improve in 2026?